X

Speakers: 

Pierre Laurin, B.Sc.Pharm., M.Sc.
President & Chief Executive Officer
ProMetic Life Sciences Inc.

Mr. Pierre Laurin has over 25 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman and CEO of the Company since its inception, he took the Company public on the Toronto Stock Exchange and has since raised over $95 million through equity financings and multinational funding. Mr. Laurin’s corporate development achievements include the successful close of some 20 licensing agreements and joint venture agreements with multinationals including the American Red Cross, Merck, and Arriva Pharmaceuticals.

Bruce Pritchard, BA, CA, FloD
Chief Operating Officer and Chief Financial Officer
ProMetic Life Sciences Inc.

Mr. Bruce Pritchard joined PLI as CFO of the UK subsidiary, ProMetic BioSciences Ltd. ("PBL") in 2006 and was promoted CFO of the group in 2008. He is a chartered accountant with many years of experience in general management and corporate accountancy including senior finance positions with biotech and pharmaceutical companies. He has a proven track record of success in strategic acquisitions and in raising debt and equity finance. Mr. Pritchard is a member of the Board of Examiners of The Institute of Directors and is a Non-Executive Director of both Imanova Limited and Being Digital Limited. He is Chair of the Audit Committee for Imanova limited. A Heriot-Watt University graduate, Mr. Pritchard gained a BA in Accountancy and Computer Science in 1993, he qualified as a Member of the Institute of Chartered Accountants of Scotland in 1996. He was appointed a Fellow of the Institute of Directors in 2014.

About ProMetic

ProMetic is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics (the study of proteins), and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission of bringing to market effective, innovative, lower cost products for the treatment of hematological and nephrological disorders and cancer. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the USA and Canada, manufacturing facilities in the UK and business development activities in the USA, Europe, Asia and in the Middle-East. ProMetic focuses its activities in the Protein Technologies and Therapeutics markets.